NCT01314209

Dexmedetomidine Pharmacokinetics During Continuous Renal Replacement Therapy (CRRT)

Dexmedetomidine Pharmacokinetics During Continuous Venovenous Hemodialysis in Critically Ill Patients

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Helsinki University Central Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine dexmedetomidine pharmacokinetics during continuous renal replacement therapy on critically ill patients.

Detailed description

Dexmedetomidine is a selective alpha-2-adrenergic agonist with sedative properties indicated for sedation of patients in the intensive care setting. ICU patients with acute kidney injury requiring renal replacement therapies frequently have changes in volume status causing alterations in drug pharmacokinetics. Although dexmedetomidine pharmacokinetics have been studied earlier on ICU patients, there is no information on its pharmacokinetics in critically ill patients needing continuous renal replacement therapy.

Conditions

• Acute Kidney Injury

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion

Timeline

• Start date: 2011-03-01
• Primary completion: 2014-03-01
• First posted: 2011-03-14
• Last updated: 2012-10-24

Locations

1 site across 1 country: Finland